TY - JOUR
T1 - Establishing clinical remission criteria and the framework of a treat-to-target algorithm for Takayasu arteritis
T2 - Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour and Welfare for intractable vasculitis
AU - Sugihara, Takahiko
AU - Nakaoka, Yoshikazu
AU - Uchida, Haruhito A.
AU - Yoshifuji, Hajime
AU - Maejima, Yasuhiro
AU - Watanabe, Yoshiko
AU - Amiya, Eisuke
AU - Tanemoto, Kazuo
AU - Miyata, Tetsuro
AU - Umezawa, Natsuka
AU - Manabe, Yusuke
AU - Ishizaki, Jun
AU - Shirai, Tsuyoshi
AU - Nagafuchi, Hiroko
AU - Hasegawa, Hitoshi
AU - Miyamae, Takako
AU - Niiro, Hiroaki
AU - Ito, Shuichi
AU - Ishii, Tomonori
AU - Isobe, Mitsuaki
AU - Harigai, Masayoshi
N1 - Funding Information:
The authors would like to acknowledge three representatives of the TAK Patient Association. This work was supported by grants from the Ministry of Health, Labour and Welfare, Japan [H29-nanchitou (nan)ippan-018 and 20FC1044] and the Japan Agency for Medical Research and Development (JP17ek0109121).
Publisher Copyright:
© Japan College of Rheumatology 2021.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Objectives: To develop a proposal for remission criteria and a framework for a treat-to-target (T2T) algorithm for Takayasu arteritis (TAK). Methods: A study group of the large-vessel vasculitis group of the Japanese Research Committee of the Ministry of Health, Labour and Welfare for Intractable Vasculitis consists of 10 rheumatologists, 5 cardiologists, 1 nephrologist, 1 vascular surgeon, 1 cardiac surgeon, and 2 paediatric rheumatologists. A Delphi survey of remission criteria items was circulated among the study group over four reiterations. To develop the T2T algorithm, the study group conducted four face-to-face meetings and two rounds of Delphi together with three patients. Results: Initial literature review resulted in a list of 117 candidate items for remission criteria, of which 56 items with a mean score of ≥4 (0–5) were extracted including disease activity domains and treatment/comorbidity domains. The study group provided six overarching principles for the T2T algorithm, two recommendations on treatment goals, five on evaluation of disease activity and imaging findings including positron emission tomography–computed tomography, and two on treatment intensification. Conclusions: We developed a T2T algorithm and proposals for standardised remission criteria by means of a Delphi exercise. These will guide future evaluation of different TAK treatment regimens.
AB - Objectives: To develop a proposal for remission criteria and a framework for a treat-to-target (T2T) algorithm for Takayasu arteritis (TAK). Methods: A study group of the large-vessel vasculitis group of the Japanese Research Committee of the Ministry of Health, Labour and Welfare for Intractable Vasculitis consists of 10 rheumatologists, 5 cardiologists, 1 nephrologist, 1 vascular surgeon, 1 cardiac surgeon, and 2 paediatric rheumatologists. A Delphi survey of remission criteria items was circulated among the study group over four reiterations. To develop the T2T algorithm, the study group conducted four face-to-face meetings and two rounds of Delphi together with three patients. Results: Initial literature review resulted in a list of 117 candidate items for remission criteria, of which 56 items with a mean score of ≥4 (0–5) were extracted including disease activity domains and treatment/comorbidity domains. The study group provided six overarching principles for the T2T algorithm, two recommendations on treatment goals, five on evaluation of disease activity and imaging findings including positron emission tomography–computed tomography, and two on treatment intensification. Conclusions: We developed a T2T algorithm and proposals for standardised remission criteria by means of a Delphi exercise. These will guide future evaluation of different TAK treatment regimens.
UR - http://www.scopus.com/inward/record.url?scp=85136893270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136893270&partnerID=8YFLogxK
U2 - 10.1093/mr/roab081
DO - 10.1093/mr/roab081
M3 - Article
C2 - 34850081
AN - SCOPUS:85136893270
SN - 1439-7595
VL - 32
SP - 930
EP - 937
JO - Modern Rheumatology
JF - Modern Rheumatology
IS - 5
ER -